Abbvie Biotechnology Ltd

John R Medich

Susan K Paulson

Peter A Noertersheuser

Robert L Wong

Rebecca S Hoffman

Christopher T Ritchlin

Hartmut Kupper

Renee J Perdok

Phillip Mease

Eric H Sasso

The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF&#x3b1; inhibitor, such as a human TNF&#x3b1; antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF&#x3b1; inhibitor.

Methods for treating juvenile idiopathic arthritis

The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF&#x3b1; inhibitor, such as a human TNF&#x3b1; antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF&#x3b1; inhibitor for treatment of psoriatic arthritis in a subject.

Uses and compositions for treatment of psoriatic arthritis

Methods for treating juvenile idiopathic arthritis by inhibition of TNF&#x3b1;

The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNF&#x3b1; inhibitor, such as a human TNF&#x3b1; antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNF&#x3b1; inhibitor for treatment of ankylosing spondylitis in a subject.

Method of treating ankylosing spondylitis

Growing community of inventors

Highland Park, IL, United States of America

John R Medich